Literature DB >> 12227731

Regression of left ventricular hypertrophy in hemodialysis patients is possible.

H Hampl1, C Sternberg, S Berweck, D Lange, F Lorenz, C Pohle, E Riedel, L Gogoll, L Hennig.   

Abstract

Regression of left ventricular hypertrophy in hemodialysis patients is possible. Left ventricular hypertrophy represents the major risk factor for cardiac morbidity and mortality. Therefore, their regression is mandatory. Since the causes of uremia-associated left ventricular hypertrophy are multifactorial, various therapeutic options can be considered: optimal control of arterial hypertension and volume status, optimal correction of metabolic acidosis, best possible correction of hypoalbuminemia and severe secondary hyperparathyroidism, modern pharmacotherapeutic strategy for the treatment of heart failure (use of angiotensin-converting enzyme inhibitors in combination with angiotensin II receptor blockers and beta-blockers) and total correction of renal anemia. Following the proposed therapeutic strategies we could, by using echocardiography, distinguish in 100 hemodialysis patients the following 3 groups (on the average after 1.5 years): 36 patients with initially normal left ventricular mass index (LVMI (g/m2), F < 110; M < 130) maintained normal (group 1); in 31 patients with moderately increased LVMI full regression resulted (group 2); 33 patients with severely increased LVMI (group 3) had to be further divided into 2 sub-groups: 22 patients with significant improvement of LVMI, 11 patients with no, regression. For the first time we were able to show that it is possible to maintain initially normal LVMI during long-term treatment and to achieve complete regression and significant improvement of LVMI in our patients. However, since LVMI requires a long time to develop, a similarly long time must be estimated for its regression. However, 11 patients remained therapeutically resistant. In this group, severe heart diseases were often combined and highly prevalent, including ischemic heart and valve diseases and end-stage dilatative cardiomyopathy. These patients had to be transferred to cardiac surgery. Anemia is considered to be one of the most important factors for the development of left ventricular hypertrophy. Therefore, total correction of renal anemia has to be strongly recommended in addition to other measures of our therapeutic strategy to maintain full or significant regression of left ventricular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12227731

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

Review 1.  Cardiorenal syndrome: still not a defined entity.

Authors:  Carlo Longhini; Christian Molino; Fabio Fabbian
Journal:  Clin Exp Nephrol       Date:  2010-02-20       Impact factor: 2.801

Review 2.  Cardiovascular complications in pediatric end-stage renal disease.

Authors:  Rulan S Parekh; Samuel S Gidding
Journal:  Pediatr Nephrol       Date:  2004-12-15       Impact factor: 3.714

3.  Reduction of left ventricular hypertrophy in children undergoing hemodialysis.

Authors:  Tim Ulinski; Julie Genty; Christine Viau; Isabelle Tillous-Borde; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2006-06-01       Impact factor: 3.714

4.  Improved blood pressure and left ventricular remodelling in children on chronic intermittent haemodialysis: a longitudinal study.

Authors:  Nabil Melhem; Alex Savis; Arran Wheatley; Helen Copeman; Kay Willmott; Christopher J D Reid; John Simpson; Manish D Sinha
Journal:  Pediatr Nephrol       Date:  2019-05-16       Impact factor: 3.714

5.  Cardio-renal anemia syndrome.

Authors:  G Efstratiadis; D Konstantinou; I Chytas; G Vergoulas
Journal:  Hippokratia       Date:  2008-01       Impact factor: 0.471

6.  Short-term evolution of cardiac structure and function in patients on maintenance hemodialysis for end-stage renal disease: A quasi-experimental, non-randomized, evaluation echocardiography study in Cameroon, sub-Saharan Africa.

Authors:  Ba Hamadou; Ingrid Balemaken; Jérôme Boombhi; Félicité Kamdem; Sylvie Ndongo Amougou; Liliane Kuate Mfeukeu; Chris Nadège Nganou; Alain Menanga; Gloria Ashuntantang
Journal:  Anatol J Cardiol       Date:  2018-01       Impact factor: 1.596

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.